肥胖合并2型糖尿病患者药物治疗与减重手术的代谢组学指纹:STAMPEDE试验
研究对STAMPEDE试验中90例肥胖合并2型糖尿病患者(随机分配至药物治疗30例、Roux-en-Y胃旁路术30例、袖状胃切除术30例)在基线和治疗24个月时进行非靶向代谢组学分析,发现袖状胃切除术和Roux-en-Y胃旁路术后循环代谢组显著重塑,而药物治疗后变化重叠较大;2-羟基癸酸在Roux-en-Y胃旁路术中具有选择性重要性,且其变化与Roux-en-Y胃旁路术后空腹血糖降低相关。
要点
- 袖状胃切除术和Roux-en-Y胃旁路术后循环代谢组显著重塑,药物治疗后变化重叠较大。
- 2-羟基癸酸对Roux-en-Y胃旁路术具有选择性重要性,是区分三种治疗的最显著特征。
- 2-羟基癸酸变化与Roux-en-Y胃旁路术后空腹血糖降低相关,与袖状胃切除术或药物治疗无关。
核心结论
- 研究识别出表征药物治疗、Roux-en-Y胃旁路术和袖状胃切除术长期适应的新型代谢组学指纹,Roux-en-Y胃旁路术和袖状胃切除术的代谢组学特征不同,提示等效减重可能通过不同的代谢效应实现。
研究设计与样本
- 对STAMPEDE试验中90例肥胖合并2型糖尿病患者(年龄49.9±7.6岁,女性57.7%)的血浆样本进行回顾性非靶向代谢组学分析,患者随机分配至药物治疗(n=30)、Roux-en-Y胃旁路术(n=30)或袖状胃切除术(n=30),在基线和治疗24个月时采用超高效液相色谱-串联质谱检测。
主要发现
- 袖状胃切除术和Roux-en-Y胃旁路术后循环代谢组显著重塑,药物治疗后变化 largely overlapping。
- 与药物治疗相比,袖状胃切除术和Roux-en-Y胃旁路术显著增强与脂质和氨基酸信号相关的代谢物浓度,同时限制外源性代谢物,后者与用药减少有关。
- 随机森林分析显示2-羟基癸酸对Roux-en-Y胃旁路术具有选择性重要性,是区分药物治疗、袖状胃切除术和Roux-en-Y胃旁路术的最显著特征。
- 2-羟基癸酸变化与Roux-en-Y胃旁路术后空腹血糖降低相关,但与袖状胃切除术或药物治疗无关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are effective procedures to treat and manage type 2 diabetes (T2D). However, the underlying metabolic adaptations that mediate improvements in glucose homeostasis remain largely elusive. The purpose of this study was to identify metabolic signatures associated with biochemical resolution of T2D after medical therapy (MT) or bariatric surgery. RESEARCH DESIGN AND METHODS: Plasma samples from 90 patients (age 49.9 ± 7.6 years; 57.7% female) randomly assigned to MT (n = 30), RYGB (n = 30), or SG (n = 30) were retrospectively subjected to untargeted metabolomic analysis using ultra performance liquid chromatography with tandem mass spectrometry at baseline and 24 months of treatment. Phenotypic importance was determined by supervised machine learning. Associations between change in glucose homeostasis and circulating metabolites were assessed using a linear mixed effects model. RESULTS: The circulating metabolome was dramatically remodeled after SG and RYGB, with largely overlapping signatures after MT. Compared with MT, SG and RYGB profoundly enhanced the concentration of metabolites associated with lipid and amino acid signaling, while limiting xenobiotic metabolites, a function of decreased medication use. Random forest analysis revealed 2-hydroxydecanoate as having selective importance to RYGB and as the most distinguishing feature between MT, SG, and RYGB. To this end, change in 2-hydroxydecanoate correlated with reductions in fasting glucose after RYGB but not SG or MT. CONCLUSIONS: We identified a novel metabolomic fingerprint characterizing the longer-term adaptations to MT, RYGB, and SG. Notably, the metabolomic profiles of RYGB and SG procedures were distinct, indicating equivalent weight loss may be achieved by divergent effects on metabolism.
引用
- Axelrod CL, Hari A, Dantas WS, et al. Metabolomic Fingerprints of Medical Therapy Versus Bariatric Surgery in Patients With Obesity and Type 2 Diabetes: The STAMPEDE Trial. Diabetes Care. 2024. PMID: 39311919. doi:10.2337/dc24-0859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。